Generic Oncology Drugs Market Size, Growth 2018-2026

Summary
Table Of Content

Industry Outlook

The generic oncology drugs market is expected to grow from US$ 17,151.0 million in 2017 to US$ 29,222.5 million by 2026, representing a compounded annual growth rate (CAGR) of 6.1% from 2018 to 2026. According to the statistics provided by the World Health Organization (WHO) in 2018, 9.6 million people worldwide have been estimated to be dead due to cancer. It is considered the second leading cause of death, and researchers are of the opinion that approximately 30% of cancer deaths can be prevented by avoiding risk factors such as alcohol consumption, tobacco smoking, early diagnosis, etc. Generic oncology drugs drastically reduce the healthcare cost burden associated with cancer treatment, but there is still ambiguity among healthcare professionals regarding their effectiveness and bioequivalence when compared to branded drugs. Healthcare agencies have made it imperative for pharmaceutical companies to follow ICH and cGMP guidelines while manufacturing generic oncology drugs.

Market Synopsis

Excellent pharmacokinetic and pharmacodynamic drug profiles are related to the positive inclination among oncologists worldwide.

Small molecules are currently dominating the oncology generic drug market. They apparently constitute 90% of the medicines currently available on the market. The chief parameters responsible for its popularity among oncologists throughout the globe are its excellent drug pharmacokinetic and pharmacodynamic profiles. Large molecules comprise biologics, which are gaining huge traction in the current scenario as they resemble biomolecules present in the human body and specifically bind to those cell receptors that are associated with disease processes, resulting in high drug efficacy, safety, and minimal side effects. The expiration of the process patent of biologics used in cancer treatment will allow their generic version to enter the market, lowering the cost burden associated with cancer.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

A significant rise in cancer patients and the increasing trend of generic substitution over branded drugs drive market growth in North America.

North America, with a market share of 42%, is the largest regional market for generic oncology drugs. According to the Centers for Disease Control and Prevention (CDC) research findings, 9.4% of adults in the United States have cancer. The drivers associated with its dominance are the rising prevalence of cancer and the increasing trend of generic substitution over branded drugs. It is state-specific in the U.S. and province-specific in Canada. Europe holds a 30% market share on account of the supportive regulatory scenario provided by the European Medical Agency (EMA) for generic oncology drugs. The presence of major players such as Teva Pharmaceutical Industries, Ltd., Mylan N.V., Merck & Co., and Novartis A.G. in Europe contributes to market growth. Asia Pacific represents 20% of the market owing to the significant rise in the number of patients diagnosed with cancer and the booming oncology generic market, which receives business leverage from government healthcare authorities to reduce the cost burden associated with cancer treatment.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026,considering 2017as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026

Report Scope by Segments

The market is segmented by molecule type and by geography.

Pharmaceutical giants having a strong foothold in the generic oncology drugs market are AstraZeneca, Plc., Bayer Healthcare AG, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Plc., Johnson & Johnson, Merck & Co., Mylan N.V., Novartis AG, and Teva Pharmaceutical Industries, Ltd.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Which pharmaceutical companies are competing in the generic oncology drug market?
What is the SWOT analysis of the generic oncology drug market?
What is the prevalence rate of different types of cancer?
What will be the performance and market demand of large molecules in the near future?
What are the primary factors contributing to the supremacy of North America in the regional market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Molecule Type
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global GOD Market Portraiture
2.2. Global GOD Market, by Molecule Type, 2017 (US$ Mn)
2.3. Global GOD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Generic Oncology Drugs (GOD) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global GOD Market, by Key Players, 2017

Chapter 4. Global Generic Oncology Drugs (GOD) Market, by Molecule Type
4.1. Overview
4.2. Small Molecule
4.3. Large Molecule

Chapter 5. Global Generic Oncology Drugs (GOD) Market, by Geography
5.1. Overview
5.2. North America GOD Market Analysis, 2016 – 2026
5.2.1. North America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.2.2. North America GOD Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe GOD Market Analysis, 2016 – 2026
5.3.1. Europe GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific GOD Market Analysis, 2016 – 2026
5.4.1. Asia Pacific GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America GOD Market Analysis, 2016 – 2026
5.5.1. Latin America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa GOD Market Analysis, 2016 – 2026
5.6.1. MEA GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA GOD Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. AstraZeneca, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Bayer Healthcare AG.
6.3. Celgene Corporation
6.4. F.Hoffman-La Roche Ltd.
6.5. GlaxoSmithKline, Plc.
6.6. Johnson and Johnson
6.7. Merck & Co.
6.8. Mylan N.V.
6.9. Novartis AG.
6.10. Teva Pharmaceutical Industries, Ltd.

List of Figures

FIG. 1 : Generic Oncology Drugs (GOD) Market: Research Methodology
FIG. 2 : GOD: Market Segmentation
FIG. 3 : Global GOD Market, by Molecule Type, 2017 (US$ Mn)
FIG. 4 : Global GOD Market, by Geography, 2017 (US$ Mn)
FIG. 5 : Attractive Investment Proposition: by Geography, 2017
FIG. 6 : Competitive Analysis: Global GOD Market, by Key Players, 2017
FIG. 7 : Global Small Molecule Market for GOD, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Large Molecule Market for GOD, 2016 – 2026 (US$ Mn)
FIG. 9 : U.S. GOD Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Canada GOD Market, 2016 – 2026 (US$ Mn)
FIG. 11 : U.K. GOD Market, 2016 – 2026 (US$ Mn)
FIG. 12 : Germany GOD Market, 2016 – 2026 (US$ Mn)
FIG. 13 : Rest of Europe GOD Market, 2016 – 2026 (US$ Mn)
FIG. 14 : China GOD Market, 2016 – 2026 (US$ Mn)
FIG. 15 : Japan GOD Market, 2016 – 2026 (US$ Mn)
FIG. 16 : Rest of Asia Pacific GOD Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Brazil GOD Market, 2016 – 2026 (US$ Mn)
FIG. 18 : Mexico GOD Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Rest of Latin America GOD Market, 2016 – 2026 (US$ Mn)
FIG. 20 : GCC GOD Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Rest of Middle East and Africa GOD Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 : Global Generic Oncology Drugs (GOD) Market Portraiture
TABLE 2 : Global GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 3 : Global GOD Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 : North America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 5 : North America GOD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 : Europe GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 7 : Europe GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Asia Pacific GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 9 : Asia Pacific GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Latin America GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 11 : Latin America GOD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Middle East and Africa GOD Market, by Molecule Type, 2016 – 2026 (US$ Mn)
TABLE 13 : Middle East and Africa GOD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 14 : AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 : Bayer Healthcare AG.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 : Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 : F.Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 : GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 : Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 : Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions

What is the size of Generic Oncology Drugs Market?

The market for Generic Oncology Drugs Market is expected to reach At 29,222.5 Mn in 2026.

What is the Generic Oncology Drugs Market CAGR?

The Generic Oncology Drugs Market is expected to see significant CAGR growth over the coming years, at 6.1%.

What is the Forecast period considered for Generic Oncology Drugs Market?

The report is forecasted to 2018-2026.

What is the base year considered for Generic Oncology Drugs Market?

The base year of this report is 2017.

Who are the major players in this market?

AstraZeneca, Plc. Bayer Healthcare AG., Celgene Corporation, F.Hoffman-La Roche Ltd., Glaxo SmithKline, Plc. are some of the major players in the global market.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –